Evaluation of Nuclear Factor of Activated T-cells (NFATc1) Expression in Non-metastatic Osteosarcoma Tissue
Akiyama, T., Dass, C., Choong, P.F. 2008. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7(11): 3461-9. https://doi.org/10.1158/15357163.MCT-08-0530
Avnet, S., Longhi, A., Salerno, M., Halleen, J., Perut, F., Granchi, D., Ferrari, S., Bertoni, F., Giunti, A., Baldini, N. 2008. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 33(6): 1231-8.
Bacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., Picci, P. 2005. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44(7): 748-55. https://doi.org/10.1080/02841860500327503
Bielack, S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., Kevric, M., Jundt, G., Kühne, T., Maas, R., Schwarz, R., Zoubek, A., Jürgens, H. 2009. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27(4): 557-65. https://doi.org/10.1200/JCO.2008.16.2305
Bratthauer, G.L. 2010. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Methods Mol Biol 588: 257-70. https://doi.org/10.1007/978-1-59745-324-0_26
Browne, R.H. 1995. On the use of a pilot sample for sample size determination. Stat Med 14(17): 1933-40. https://doi.org/10.1002/sim.4780141709
Buchholz, M., Schatz, A., Wagner, M., Michl, P., Linhart, T., Adler, G., Gress, T., Ellenrieder, V. 2006. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25(15): 3714-24. https://doi.org/10.1038/sj.emboj.7601246
Chua, H.H., Tuan Sharif, S.E., Wan Ismail, W.F.N., Zawawi, M.S.F., Abdullah, S. 2021. Evaluation of the receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteosarcoma and its association with the clinicopathological data. Asian Pac J Cancer Prev 22(3): 741-7. https://doi.org/10.31557/APJCP.2021.22.3.741
Endo-Munoz, L., Evdokiou, A., Saunders, N.A. 2012. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta 1826(2): 434-42. https://doi.org/10.1016/j.bbcan.2012.07.003
Faisham, W.I., Mat Saad, A.Z., Alsaigh, L.N., Nor Azman, M.Z., Kamarul Imran, M., Biswal, B.M., Bhavaraju, V.M., Salzihan, M., Hasnan, J., Ezane, A., Ariffin, N., Norsarwany, M., Ziyadi, M., Wan Azman, W., Halim, A., Zulmi, W. 2017. Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia Pac J Clin Oncol 13(2): e104-10. https://doi.org/10.1111/ajco.12346
Fletcher, C.D.M., Unni, K., Mertens, F. 2002. Pathology and genetics of tumours of soft tissue and bone. WHO Classification of Tumours: IARC Press. Giuliani, A., Colognesi, D., Ricco, T., Roncato, C., Capece, M., Amoroso, F., Wang, Q., De Marchi, E., Gartland, A., Di Virgilio, F., Adinolfi, E. 2014. Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS One 9(9): e107224. https://doi.org/10.1371/journal.pone.0107224
Hanaki, S., Habara, M., Tomiyasu, H., Sato, Y., Miki, Y., Masaki, T., Shibutani, S., Shimada, M. 2024. NFAT activation by FKBP52 promotes cancer cell proliferation by suppressing p53. Life Sci Alliance 7(8): e202302426. https://doi.org/10.26508/lsa.202302426
Huang, B., Jiang, Z., Wu, S., Wu, H., Zhang, X., Chen, J., Zhao, F., Liu, J. 2021. RCAN1.4 suppresses the osteosarcoma growth and metastasis via interfering with the calcineurin/NFAT signaling pathway. J Bone Oncol 30: 100383. https://doi.org/10.1016/j.jbo.2021.100383
Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T., Takeya, T. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277(43): 41147-56. https://doi.org/10.1074/jbc.M205063200
Li, J., Sarosi, I., Yan, X, Morony, S., Capparelli, C., Tan, H., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C.R., Lacey, D.L., Boyle, W.J. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97(4); 1566-71. https://doi.org/10.1073/pnas.97.4.1566
Li, Z., Zhang, Y., Li, Y., Xing, S., Li, S., Lyu, J., Ban, Z. 2022. PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells. Exp Ther Med 24(6): 750. https://doi.org/10.3892/etm.2022.11686
Lin, Y., Song, Y., Zhang, Y., Shi, M., Hou, A., Han, S. 2023. NFAT signaling dysregulation in cancer: Emerging roles in cancer stem cells. Biomed Pharmacother 165: 115167. https://doi.org/10.1016/j.biopha.2023.115167
Liu, W., Hao, Y., Tian, X., Jiang, J., Qiu, Q. 2022. The role of NR4A1 in the pathophysiology of osteosarcoma: A comprehensive bioinformatics analysis of the single-cell RNA sequencing dataset. Front Oncol 12: 879288. https://doi.org/10.3389/fonc.2022.879288
Mirabello, L., Troisi, R., Savage, S. 2009a. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 115(7): 1531-43. https://doi.org/10.1002/cncr.24121
Mirabello, L., Troisi, R., Savage, S. 2009b. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125(1): 229-34. https://doi.org/10.1002/ijc.24320
Neal, J.W., Clipstone, N.A. 2003. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J Biol Chem 278(19): 17246-54. https://doi.org/10.1074/jbc.M300528200
Oikawa, T., Nakamura, A., Onishi, N., Yamada, T., Matsuo, K., Saya, H. 2013. Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. Cancer Res 73(16): 5100-9. https://doi.org/10.1158/00085472.CAN-13-0274
Pan, M.G., Xiong, Y., Chen, F. 2013. NFAT gene family in inflammation and cancer. Curr Mol Med 13(4): 543-54. https://doi.org/10.2174/1566524011313040007
Papakonstantinou, E., Athanasiadou, K., Markozannes, G., Tzotzola, V., Bouka, E., Baka, M., Moschovi, M., Polychronopoulou, S., Hatzipantelis, E., Galani, V., et al. 2024. Prognostic factors in highgrade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis. Cancer Epidemiol 90: 102551. https://doi.org/10.1016/j.canep.2024.102551
Perret, R., Escuriol, J., Velasco, V., Mayeur, L., Soubeyran, I., Delfour, C., Aubert, S., Polivka, M., Karanian, M., Meurgey, A., Le Guellec, S., Weingertner, N., Hoeller, S., Coindre, J., Larousserie, F., Pierron, G., Tirode, F., Le Loarer, F. 2020. NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Mod Pathol 33(10): 1930-44. https://doi.org/10.1038/s41379-0200542-z
Pilavaki, P., Gahanbani Ardakani, A., Gikas, P., Constantinidou, A. 2023. Osteosarcoma: Current concepts and evolutions in management principles. J Clin Med 12(8): 2785. https://doi.org/10.3390/jcm12082785
Shen, T., Yue, C., Wang, X., Wang, Z., Wu, Y., Zhao, C., Chang, P., Sun, X., Wang, W. 2021. NFATc1 promotes epithelial-mesenchymal transition and facilitates colorectal cancer metastasis by targeting SNAI1. Exp Cell Res 408(1): 112854. https://doi.org/10.1016/j.yexcr.2021.112854
Smeland, S., Bielack, S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M.D., Gorlick, R., Janeway, K., Ingleby, F., Anninga, J., et al. 2019. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109: 36-50. https://doi.org/10.1016/j.ejca.2018.11.027
Szuhai, K., Ijszenga, M., de Jong, D., Karseladze, A., Tanke, H., Hogendoorn, P. 2009. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 15(7): 2259-68. https://doi.org/10.1158/1078-0432.CCR-08-2184
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E.F., Mak, T.W., Kodama, T., Taniguchi, T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6): 889-901. https://doi.org/10.1016/s15345807(02)00369-6
Velupillai, P., Sung, C., Tian, Y., Dahl, J., Carroll, J., Bronson, R., Benjamin, T. 2010. Polyoma virusinduced osteosarcomas in inbred strains of mice: Host determinants of metastasis. PLoS Pathog 6(1): e1000733. https://doi.org/10.1371/journal.ppat.1000733
Wadhwa, N. 2014. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J Orthopaedics 48(3): 247-54. https://doi.org/10.4103/0019-5413.132497
Wang, L., Mao, X., Yu, X., Su, J., Li, Z., Chen, Z., Ren, Y., Huang, H., Wang, W., Zhao, C., Hu, Y. 2024. FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway. Cancer Lett 593: 216841. https://doi.org/10.1016/j.canlet.2024.216841
Yasin, N., Abdul Rashid, M., Ajit Singh, V. 2020. Survival analysis of osteosarcoma patients: A 15-year experience. J Orthop Surg 28(1): 2309499019896662. https://doi.org/10.1177/2309499019896662
Zawawi, M.S.F., Dharmapatni, A.A.S.S.K., Cantley, M.D., McHugh, K.P., Haynes, D.R., Crotti, T.N. 2012. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurinNFAT signalling during late stage osteoclast differentiation. Biochem Biophys Res Commun 427(2): 404-9. https://doi.org/10.1016/j.bbrc.2012.09.077
